Biopharmaceutical business Dimerix (ASX:DXB) should see boosted recruitment rates in the UK for its trial of focal segmental glomerulosclerosis (FSGS) after it entered a collaboration with the largest rare kidney disease registry in the world, the UK's National Registry of Rare Kidney Diseases (RaDaR), according to a research note from Euroz Hartleys.
RaDaR has more than 34,500 rare kidney disease patients recruited from 109 hospitals in the UK, with plans to identify patients suitable for Phase 3 of Dimerix's trial, the note stated.
Euroz Hartleys maintained its speculative buy rating and AU$0.91 price target on Dimerix.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。